Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

PrintyMed—Biomimetic spider silk membranes for Organ-on-a-Chip solutions

Obiettivo

Drug development remains slow, risky, and inefficient: it takes 10–15 years, costs €1–2B per approved drug, and over 90% of candidates fail, largely due to inadequate preclinical models. As innovation slows and costs rise, regulators in the EU and US increasingly mandate human-relevant, non-animal methods. Organ-on-Chip (OoC) systems offer physiological relevance, yet their adoption is restricted by one critical bottleneck: the membrane. Current membranes absorb drugs, lack physiological elasticity, require unstable animal-derived coatings, and degrade under flow, limiting OoC performance.
PrintyMed addresses this limitation with a proprietary biomimetic spider silk. Engineered to replicate natural spinning, we combine recombinant mini-spidroins optimized for microbial expression with controlled molecular self-assembly and a patented PEG-based tuning step for precise control of mechanics and surface chemistry.
In this project, we will complete the engineering optimisation and validation of our ultrathin, elastic, permeable, optically clear, biocompatible spider-silk membrane and establish a reproducible, scalable, water-based manufacturing process. We will benchmark mechanical, chemical, and biological performance, and integrate the membrane into a state-of-the-art Gut-on-Chip to reach TRL 6. We will validate intrinsic cell adhesion, growth, TEER stability, and barrier function without animal-derived coatings, confirming the membrane as ready for OoC deployment. We will prepare a draft patent application and outline the regulatory and industrial scale-up roadmap. Newly generated IP on OoC-specific membrane architectures and surface chemistries will position PrintyMed as the first specialised supplier of medical-grade, tunable, biomimetic membranes in the rapidly growing market. By unlocking the missing materials layer for next-generation OoC systems, PrintyMed enables more predictive drug testing, fewer clinical failures, and faster therapeutic development.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-CSA - HORIZON Coordination and Support Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-WIDERA-2025-02

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

PRINTYMED
Contributo netto dell'UE
€ 500 000,00
Indirizzo
TOMINI CENU PAG JELGAVAS NOV
LV-3018 JELGAVAS NOVADS
Lettonia
PMI
Sì
Regione
Latvija Latvija Zemgale
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
Nessun dato